Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Home is an important treatment modality, as it offers qualifying patients the opportunity for more flexibility in treatments and an improved quality of life |
| Thanks to the hard work and dedication of our teams around the world, we have successfully executed on our commitment of fundamental transformation, making progress against all facets of our plan |
| We are continuing to see an increasing Medicare Advantage book of business sitting at around 40% now, which is really encouraging |
| And throughout 2023, our commitment to our operational turnaround initiatives helped drive organic growth in both segments and improving operational performance |
| Our FME25 transformation program delivered savings ahead of schedule while ensuring our company becomes stronger and more resilient in the future |
| When I look back at everything we accomplished in 2023 and the foundation we laid, I'm very optimistic about what we will be able to achieve this year and beyond |
| Based on the outlook base and assumptions I just described, we expect revenue to continue to grow by a low- to mid-single digit percent rate and operating income to grow by a mid- to high-teens percent rate in 2024 |
| So, we are thrilled, excited, a gamechanger |
| And finally, our relentless focus on improving operating performance allowed us to upgrade our outlook for the first time in the company's history |
| And I'm very proud to say that we even exceeded our upgraded outlook, and we did a little bit more than we said we would do |
| We achieved revenue growth at the top end of our outlook range and organic growth in the year was mainly driven by favorable business developments |
| This makes us optimistic for a positive growth development for 2024, which we have included with a careful assumption as the basis for our outlook for this year |
| As I mentioned, our earnings exceeded the top end of our upgraded outlook, thanks to business growth, realized FME25 savings ahead of plan, and the Tricare settlement |
| Contributing to the earnings growth were faster-than-expected labor productivity improvements in Care Delivery as well as positive impacts from our pricing initiatives in Care Enablement |
| The strict commitment to our stringent financial policy resulted in significantly improved cash flow and an important decrease in our net leverage ratio |
| As I discussed earlier, our FME25 transformation has successfully delivered sustainable savings through 2023 |
| Obviously, we got really thrilled with the FDA approval, which came kind of a few weeks earlier than we anticipated |
| Looking ahead to 2024, we are confident in our ability continue to improve our cash flow and further strengthen our financial position |
| We continued to deliver cash flow improvement through the fourth quarter, and for the full year 2023, we realized an operating cash flow improvement of 21% |
| FME25 savings were a strong tailwind in the quarter, as we continue to drive clinical operational efficiencies |
| Obviously, on CE, we know that we were starting from a low -- sorry, switching to your second question, we know, on CE, we were starting from a low base, and I think we made some really nice progress in '23 on pricing and overall efficiencies |
| During the fourth quarter, operating income, on a guided basis, improved by 18%, and our group margin improved to 11% |
| Along with the solid top-line growth, the successful execution of our turnaround initiatives translated into improved earnings |
| Our operating income increased 15% in constant currency, and our group margin expanded 100 basis points to 8.9% |
| We are making important progress towards our 2025 group margin target, which is supported by our FME25 program, where we realized €346 million in savings through the end of 2023, well ahead of our plan |
| The €181 million Tricare settlement proceeds was another positive earnings driver, for which we increased our outlook the second time in 2023 |
| And we realized meaningful labor productivity improvements in Care Delivery that we originally only expected to realize in 2024 |
| Earnings in the fourth quarter were supported by strong FME25 savings, as well as proceeds from the Tricare settlement in the US and improved pricing and Care Enablement |
| The market dynamic is strong |
| We continued to deliver solid organic growth, revenue growth and contributions from both operating segments |
| Statement |
|---|
| In addition, the negative EBIT contribution from value-based care was in the fourth quarter driven by retrospective CKCC model trend adjustments |
| I think you all know we're disappointed with the reimbursement rate on PPS |
| While this development was revenue supportive, we experienced a negative earnings contribution in the fourth quarter driven by CKCC retrospective trend adjustments |
| Clearly, we had an underperformance in the Q4 compared to that |
| So, on the CKCC topic for the quarter, we incurred about a €60 million loss of negative operating income in the quarter |
| As we already outlined in our Q3 earnings call, this included around €40 million in NCB deconsolidation gains and around €40 million in leadership bonus plan favorability, given weaker company performance in 2022 and outperformance in 2023 |
| Operating income development for Care Delivery faced a meaningful headwind from currency translation effect in the quarter |
| Inflation continued to be a headwind in the quarter, in particular due to higher material prices |
| Others, we do absolutely hedge, but there's uncertainties like in things like Russia |
| We did see a tick-up in mistreatments in Q4, kind of weather and kind of flu and COVID effects in Q4, which really unfortunately impacted our respective volume |
| This negatively offset our business development in the quarter |
| So, it seems like transactional FX was a pretty big headwind to the business in FY '23 and is going to be a headwind again in 2024 |
| Net of labor productivity, we assume a €150 million to €200 million labor cost headwind for the group |
| And while we have made significant progress, we do still have some constrained clinics and some labor challenges that we are working through |
| We expect a headwind of €100 million to €150 million for other cost inflation in both Care Delivery and Care Enablement |
| You also saw that this is coming down year-over-year, and yes, we are hedging against those topics |
| So, those €60 million is something that also when you consider the full year turns our full year CKCC into a €10 million negative that you can like assume after quarter four |
| And we -- like with SGLT2s, they've been on the market a decade, we have a very slow, a small uptick -- kind of uptake, with it being around 8% there |
| I think we ended up being impacted in the quarter with the mistreatment, as I mentioned |
| We have a mild one this year |
Please consider a small donation if you think this website provides you with relevant information